RPID — Rapid Micro Biosystems Inc

Rapid Micro Biosystems Inc (RPID) is a medical devices company listed on NASDAQ. It is led by Robert G. Spignesi Jr., based in 25 Hartwell Avenue, Lexington, MA, United States, 02421, with about 171 employees. Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biologics, medical devices, and personal care products in the United States, Switzerland, Germany, Japan, and internationally. The company offers Growth Direct platform, which includes growth direct system, proprietary consumables, lab information management system connection software, and customer support and validation services. Its platform automates and modernizes the antiquated, manual microbial quality control (MQC), testing workflows for therapeutic modalities, such as biologics and cell and gene therapies, vaccines, and sterile injectables. The company also provides onsite technical training services. Its solutions are used in environmental monitoring, water, bioburden, and sterility release testing applications. In addition, the company offers RMBNucleus Mold Alarm software; and Growth Direct LIMS connection software. Rapid Micro Biosystems, Inc. was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

Latest reported RPID revenue for 2025-09-30 was $7.8M. Net income was -$11.5M. Revenue was up 7.9% from 2025-06-30 to 2025-09-30. RPID currently screens at market cap $85.7M.

Use this RPID page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the RPID quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the RPID SEC filings page. Lician reads the product cache first so this HTML stays unique to Rapid Micro Biosystems Inc even when a live quote feed is slow.